Orchestra BioMed Holdings (OBIO) Current Deferred Revenue (2021 - 2025)

Orchestra BioMed Holdings (OBIO) has 5 years of Current Deferred Revenue data on file, last reported at $4.6 million in Q3 2025.

• On a quarterly basis, Current Deferred Revenue rose 14.34% year-over-year to $4.6 million in Q3 2025; TTM through Sep 2025 was $4.6 million, a 14.34% increase from a year earlier, with the FY2024 full-year figure at $4.4 million, up 76.85% from the prior year.
• Current Deferred Revenue for Q3 2025 stood at $4.6 million, up from $4.5 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for OBIO reached as high as $22.4 million in Q4 2021 and fell as low as $2.5 million in Q4 2023.
• Historically, Current Deferred Revenue has averaged $7.7 million across 5 years, with a median of $4.4 million in 2023.
• On a YoY basis, Current Deferred Revenue climbed as much as 76.85% in 2024 and fell as far as 83.42% in 2024.
• Year by year, Current Deferred Revenue stood at $22.4 million in 2021, then sank by 71.27% to $6.4 million in 2022, then slumped by 61.0% to $2.5 million in 2023, then soared by 76.85% to $4.4 million in 2024, then gained by 4.73% to $4.6 million in 2025.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $4.6 million in Q3 2025, $4.5 million in Q2 2025, and $3.9 million in Q1 2025.